1302 — LifeTech Scientific Balance Sheet
0.000.00%
- HK$8.66bn
- HK$7.71bn
- CNY1.30bn
- 72
- 22
- 63
- 54
Annual balance sheet for LifeTech Scientific, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,143 | 1,476 | 834 | 1,179 | 1,182 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 177 | 199 | 260 | 503 | 543 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,545 | 1,837 | 1,397 | 2,231 | 2,334 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 500 | 744 | 816 | 921 | 1,003 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,955 | 3,184 | 3,690 | 4,696 | 4,900 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 494 | 482 | 585 | 770 | 816 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 614 | 680 | 790 | 1,326 | 1,406 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 2,340 | 2,504 | 2,900 | 3,370 | 3,495 |
| Total Liabilities & Shareholders' Equity | 2,955 | 3,184 | 3,690 | 4,696 | 4,900 |
| Total Common Shares Outstanding |